Beta1-adrenergic receptor (β 1 -AR) belongs to G protein-coupled receptors, regulating cardiac physiological and pathological process through complex signaling pathways. Physiologically, the activation of β 1 -AR produces positive chronotropic, positive inotropic and positive dromotropic effects in the heart. However, excessive or sustained activation of β 1 -AR can cause myocardial injury, arrhythmias, and heart failure. The β 1 -AR in the heart exhibits tissue-specific distribution patterns and subcellular localization features adapted to its function within cardiomyocytes. Upon ligand binding, the β 1 -AR undergoes conformational changes and transmits signaling through G protein-dependent pathways (β 1 -AR/Gs and β 1 -AR/Gi) as well as a G protein-independent pathway (β 1 -AR/β-arrestin) to regulate cardiac activity. Subsequently, the β 1 -AR can either dissociate from G protein to undergo desensitization and terminate signal transduction, or it can be endocytosed into the cell, transported to the lysosome to be degraded, or returned to the plasma membrane to continue its function. Additionally, it has been found that β 1 -AR can cause or exacerbate heart disease when abnormal changes occur in its distribution density, localization, and mediated downstream signaling pathways. Therefore, β 1 -AR represents an important pharmacotherapeutic target for the treatment of cardiac diseases. Among the relevant therapeutic agents, β 1 -AR blockers designed specifically against β 1 -AR have evolved to the third generation. This review comprehensively analyzes β 1 -AR from perspectives including its research history, expression, and distribution in the heart, protein structure, signaling pathways, and associations with cardiac diseases.
Atherosclerosis constitutes the primary pathological basis for cardiovascular diseases. It most commonly develops at the branching and curved regions of blood vessels. The disturbed blood flow in these regions can generate oscillatory shear stress (OSS). Endothelial cells exposed to OSS progressively undergo a transformation into mesenchymal cells, a process known as endothelial-to-mesenchymal transition (EndMT). EndMT is a critical event in the development of atherosclerosis. OSS promotes the occurrence of EndMT through multiple pathways. This paper provides a comprehensive analysis of the phenomena and mechanisms of OSS-induced EndMT, offering theoretical insights into the pathogenic mechanisms of atherosclerosis and corresponding therapeutic strategies.
Background The β1-adrenergic receptor (β1-AR) is an important membrane receptor belonging to the G protein coupled receptors, encoded by ADRB1. Norepinephrine released by the sympathetic nerve activates β-adrenergic receptors. Compared with β2-adrenergic receptor (β2-AR), β1-AR has higher affinity for norepinephrine. However, the current research is mostly limited to the role of β2-AR in cancer development, and the effect and mechanism of β1-AR on cancer prognosis are still unclear. Methods We analyzed ADRB1 expression in different types of cancer and corresponding normal tissues. The correlation between ADRB1 expression and pathological grade, stage and survival of cancers were analyzed. We explored the methylation level of ADRB1 in various cancers. The cBioPortal website was used to determine the mutation characteristics of ADRB1 in cancer tissues. Additionally, the CancerSEA website was employed to explore the correlation between ADRB1 expression and different functional states in cancers. We also analyzed the correlation between ADRB1 expression and immune checkpoint (ICP) genes, tumor mutation burden (TMB), microsatellite instability (MSI), neoantigens and cancer-infiltrating immune cells. Results Our results showed that ADRB1 expression was downregulated in the majority of solid cancers. The ADRB1 expression was significantly associated with the prognosis of cancer. High expression of ADRB1 was found to be a protective factor for patients with several types of cancer. In some cancers, ADRB1 expression was associated with clinical pathological stages. Functional relevance analysis indicated the crucial role of ADRB1 in regulating multiple biological behaviors of cancer cells. The expression of ADRB1 was associated with TMB, MSI, neoantigens and immune cell infiltration in cancers. Conclusions These comprehensive pan-cancer analysis suggested that ADRB1 plays a protective role in various cancer types, such as skin cutaneous melanoma and lung adenocarcinoma. This may provide a new idea for the clinical treatment of cancer patients.
Background Lung adenocarcinoma (LUAD) is the most common pathological subtype of lung cancer. Sympathetic activation remodels the tumor microenvironment through β-adrenergic receptors (β-ARs) and is associated with malignant progression. Research mainly focuses on β2-AR, while the role of β1-AR (ADRB1) remains unclear. Methods We analyzed ADRB1 expression in LUAD versus normal tissues, A549 cells and evaluated its association with survival. Cox regression assessed relationships between clinicopathological features and prognosis. We examined ADRB1 expression and pathological stage, and used gene set enrichment analysis to explore its biological functions. Associations with tumor-infiltrating immune cells and immune checkpoint genes were investigated, and potential therapeutic drugs were screened. Results ADRB1 expression was significantly downregulated in LUAD. ADRB1 was identified as an independent protective factor for patients with LUAD. Functional enrichment analysis showed that ADRB1 was mainly involved in chromosome segregation, cell division, mitotic cytokinesis and DNA replication in LUAD. These findings were further confirmed by in vitro experiments. Bioinformatics immune infiltration analysis revealed a significant correlation between ADRB1 expression and neutrophil infiltration abundance in lung adenocarcinoma (LUAD), suggesting that ADRB1 might be associated with the tumor immune microenvironment. In two independent LUAD cohorts, ADRB1 showed a significant negative correlation with the immune checkpoint CD276, leading to the speculation that the impact of ADRB1 on LUAD prognosis might be related to CD276 expression. Through computational screening, AZD7762 was provisionally identified as potential therapeutic agents for LUAD. Conclusions In vitro assays verified that ADRB1 suppressed A549 cell proliferation and migration, supporting its function as a tumor suppressor and independent prognostic biomarker for LUAD. Transcriptomic bioinformatic analyses identified correlative links between ADRB1, neutrophil infiltration and CD276 expression. AZD7762 could serve as a potential therapeutic candidate for LUAD patients.